The expression of programmed death receptor ligand 1 (PD-L1) can be determined by an immunohistochemistry (IHC) assay, a widely used selection method for pembrolizumab treatment in gastric cancer (GC) patients. This evidence concerns the gene CD274 and gastric cancer.